Hylenex

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pain

Conditions

Pain

Trial Timeline

Jan 1, 2006 → Oct 1, 2006

NCT ID

NCT00593281

About Hylenex

Hylenex is a phase 3 stage product being developed by Halozyme Therapeutics for Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00593281. Target conditions include Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00435604	Phase 1	Completed	Feb 1, 2007	May 1, 2007	Healthy
NCT00593281	Phase 3	Completed	Jan 1, 2006	Oct 1, 2006	Pain
NCT00311519	Approved	Completed	Nov 1, 2005	Jan 1, 2006	Healthy

Competing Products

20 competing products in Pain

See all competitors

Product	Company	Stage	Hype Score
PRF110- oily solution (Ropivacaine)	PainReform	Phase 2	44
PRF110	PainReform	Phase 2	44
PRF-108 + Placebo + Ropivacaine + PRF-110	PainReform	Phase 1/2	33
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + Placebo	Trevena	Phase 1	25
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
TRV130	Trevena	Phase 3	69
TRV130 + Morphine + Placebo	Trevena	Phase 2	44
TRV130	Trevena	Phase 2	44
LY3556050 + Placebo	Eli Lilly	Phase 2	52
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) Tablets	Nanoform Finland	Phase 1	28
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine	SI-BONE	Approved	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
OK-101 0.05% + OK-101 0.1% + Placebo	OKYO Pharma	Phase 2	44
YHD1119 + Lyrica	Yuhan	Phase 1	33
YHD1119 + Lyrica	Yuhan	Phase 1	33
YHD1119 + Lyrica	Yuhan	Phase 3	77
YHD1119 300mg + YHD1119 300mg	Yuhan	Phase 1	33

Other Products from Halozyme Therapeutics

Commercial Hylenex® recombinant (hyaluronidase human injection) + Precommercial Hylenex recombinant (hyaluronidase human injection) + Insulin lispro + Insulin aspart + Insulin glulisineApproved

HylenexApproved

large protein moleculeApproved

Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lisproApproved

Rapid Acting insulin with pre-treatment of rHuPH20Approved